Effects of Bezafibrate—A Hypolipidemic Drug

Ståhlberg, Dagny

doi:10.1111/j.1527-3466.1992.tb00250.x

Cited by 8 publications

(4 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the 10 mgkg body weight perd administered intragastrically by Stegmeier et al (1980) to normolipidaemic non-human primates, the dose in our study might have been too small to lower TAG. A significant dose-response relationship for plasma cholesterol and TAG concentrations has been reported for BF (Stahlberg, 1992).…”

Section: Discussionmentioning

confidence: 90%

“…BF is an effective lipid-lowering agent in human subjects as well as in animal models (Stahlberg, 1992). The recommended dosage of the sustained formulation is 400 mg/d (6.7 mgkg for an adult weighing 60 kg).…”

Section: Discussionmentioning

confidence: 99%

“…Among such drugs, fibrates have been widely used for many years. Bezafibrate (BF), one of the new derivatives of clofibrate, is a well-tolerated drug with effective hypolipidaemic properties and has the ability to lower raised plasma fibrinogen (Stahlberg, 1992). Fibrate treatment reduces PAI-1 levels in hypertriacylgl ycerolaemic patients in whom triac ylglycerol (TAG) levels are normalized (Keber et al 1994).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Soluble-fibre concentrate lowers plasminogen activator inhibitor-1 in baboons (Papio ursinus)

et al. 1997

View full text Add to dashboard Cite

The effects of a soluble NSP (fibre) concentrate (SFC) on plasma fibrinogen and plasminogen activator inhibitor-1 (PAI-1), serum and liver lipids and lipoproteins and glucose tolerance were compared with those of bezafibrate (BF), a lipid-lowering drug, in obese baboons (Pupio ursinus). The basal diet was a high-fat (37% of total energy), low-NSP (12.4gld) Westernized diet, supplemented for 8 weeks with either 20 SFCghaboon per d or 6.7 mg BFkg body weight per baboon per d. SFC supplementation significantly lowered PAI-1, total serum cholesterol, HDLcholesterol and circulating free fatty acid levels. BF significantly lowered total serum cholesterol, but unexpectedly raised serum triacylglycerol levels. Although not statistically significant, the mean liver tricacylglycerol concentration of baboons fed on BF was lower than that of baboons fed on SFC supplements. These results suggest that: (1) the mechanism of action of the two cholesterol-lowering treatments differ, with BF having a liver triacylglycerol-lowering effect and (2) the SFC had additional beneficial effect on fibrinolysis by lowering PAL1 levels.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Soluble-fibre concentrate lowers plasminogen activator inhibitor-1 in baboons (Papio ursinus)

et al. 1997

View full text Add to dashboard Cite

show abstract

“…They increase the rate of VLDL catabolism by stimulating lipoprotein lipase activity and/or hepatic lipase activity [57], thereby lowering mainly plasma triglycerides. Other effects are inhibition of cholesterol synthesis and increase in excretion of neutral sterols [58].…”

Section: Aryloxyisobutyric Acids Derivatives and Analogsmentioning

confidence: 99%

Cardiovascular Drugs

Hollmann¹,

Lehmann²,

Albrecht³

et al. 2000

Ullmann's Encyclopedia of Industrial Chemistry

View full text Add to dashboard Cite

Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α-hydroxylase

et al. 1995

Self Cite

View full text Add to dashboard Cite

Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal-weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7 alpha-hydroxylase activity was reduced by approximately 60% in the bezafibrate treated patients compared with the controls, whereas the acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low-density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7 alpha-hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy.

show abstract

Effects of Bezafibrate—A Hypolipidemic Drug

Cited by 8 publications

References 78 publications

Soluble-fibre concentrate lowers plasminogen activator inhibitor-1 in baboons (Papio ursinus)

Soluble-fibre concentrate lowers plasminogen activator inhibitor-1 in baboons (Papio ursinus)

Cardiovascular Drugs

Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α-hydroxylase

Contact Info

Product

Resources

About